Gastric cancer

Researchers are testing a new CAR-T cell therapy called KD-496 in people with advanced solid tumors, including gastric and pancreatic cancer, that have not responded to at least two prior treatments. The therapy uses a patient's own T cells, which are genetically modified to reco…

This early-phase study tests a personalized mRNA cancer vaccine (XH001) given alongside standard treatment after surgery for people with high-risk solid tumors (bile duct, gallbladder, pancreatic, liver, or stomach cancer). The main goals are to check safety and see if the vaccin…

This early-stage trial tests an experimental oral drug called CSCJC3456 in 102 people with advanced solid tumors that have not responded to standard treatments. The study aims to find a safe dose and check for any signs that the drug can shrink tumors. Participants take the table…

This clinical trial is testing whether adding the immunotherapy drug nivolumab to standard chemotherapy (paclitaxel and ramucirumab) can help people with advanced stomach or esophageal cancer live longer. The study includes 224 adults whose cancer has a specific marker (PD-L1 CPS…

This early-phase trial tests a combination of two drugs, neratinib and fam-trastuzumab deruxtecan (Enhertu), in people with advanced stomach, esophageal, or other gastrointestinal cancers that have a specific marker called HER2. The study aims to find the safest dose and see if t…

This early-stage trial tests an experimental oral drug called SHY-ONC6 in people with advanced or metastatic solid tumors (including breast, colon, lung, pancreatic, and others) that have stopped responding to standard treatments. The study aims to find a safe dose and check for …

This phase 2 trial is testing an experimental drug called patritumab deruxtecan (HER3-DXd) in 740 people with advanced solid tumors, including melanoma, lung, breast, and other cancers. The drug is given by IV every three weeks. The main goal is to see if the drug shrinks tumors.…

This early-stage trial is testing a new drug called IM-1617 in people with advanced solid tumors (cancers that have spread or can't be removed by surgery). The study has two parts: first, finding a safe dose, then testing that dose in more people to see how well it works and how …

This early-stage study is testing a new drug called BGB-B2033, alone or with other drugs, in people with advanced liver, stomach, or lung cancers. The goal is to see if it is safe and how well it works. About 392 participants will take part.

This phase 2 trial tests whether specially selected immune cells taken from a patient's own tumor, grown in large numbers in the lab, and given back along with the drug pembrolizumab (Keytruda) can shrink tumors in people with metastatic colorectal, pancreatic, ovarian, breast, o…

This study tests an oral drug called NEO212 in people with specific brain tumors (astrocytoma, glioblastoma) or cancers that have spread to the brain. The goal is to find the safest dose and see if it helps control tumor growth. About 134 adults will take NEO212 alone or with sta…

This clinical trial is testing a new biological therapy called GAIA-102, alone or combined with the immunotherapy pembrolizumab, for people with advanced stomach or pancreatic cancer that has spread and caused fluid buildup in the abdomen (malignant ascites). The study has two pa…

Researchers are comparing a new combination of disitamab vedotin, sintilimab, and S-1 against the standard regimen of trastuzumab plus chemotherapy, with or without sintilimab, for people with advanced HER2-positive gastric or gastroesophageal junction cancer. The trial enrolls a…

This early-phase trial tests SL-28, a cell therapy made from donor immune cells, in 60 people with advanced solid tumors (like lung, pancreatic, or breast cancer) that haven't responded to standard treatments. The study aims to find a safe dose and see if the therapy can shrink t…

Researchers are testing whether adding an experimental drug called 2141-V11 to standard immunotherapy is safe for people with advanced esophageal, gastric, or gastroesophageal junction adenocarcinoma. Participants receive injections of 2141-V11 directly into their tumors along wi…

This Phase 3 trial is testing whether a new drug called rilvegostomig, combined with trastuzumab deruxtecan and chemotherapy, works better than the current standard treatment for HER2-positive stomach cancer that has spread. About 840 people whose tumors have a specific protein (…

This Phase 1 trial tests a new drug called BL-M07D1 in 280 adults with advanced HER2-positive cancers, including breast, lung, and stomach cancers. The study aims to find safe doses and check for early signs of tumor shrinkage. Participants must have tried at least two prior trea…

This clinical trial is looking at the best timing for local treatments like surgery or radiation in people with esophageal or stomach cancer that has spread to only a few spots. All participants first get 4 months of standard drug therapy. Then, depending on their response, they …

Researchers are testing two investigational radiopharmaceuticals in adults with advanced solid tumors, including colorectal, pancreatic, biliary tract, gastric, esophageal, and head and neck cancers. First, participants receive SKL35502, an imaging agent that highlights tumors ca…

This early-stage trial tests a new drug called M7437 in people with advanced solid tumors that have not responded to standard treatments. M7437 is an antibody-drug conjugate designed to deliver chemotherapy directly to cancer cells that have a specific marker (Ly6E). The study ai…

This Phase 3 trial is testing whether a new targeted drug called sonesitatug vedotin, combined with chemotherapy (capecitabine) and possibly an immunotherapy (rilvegostomig), can help people with advanced stomach, gastroesophageal junction, or esophageal cancer that has a specifi…

This early-stage trial tests a new drug called IAM1363 in adults with advanced cancers that have HER2 alterations, including breast, lung, and stomach cancers that have spread to the brain. The study aims to find the safest dose and see if the drug can shrink tumors. About 383 pa…

This phase 2 trial tests whether apatinib, taken as a daily pill, can control advanced stomach or gastroesophageal junction cancer in people aged 65 and older who cannot or will not undergo chemotherapy. Participants receive apatinib until the disease worsens or side effects beco…

This early-stage study tests a combination of two drugs—trastuzumab deruxtecan and azenosertib—in people with HER2-positive stomach, gastroesophageal junction, or other solid tumors that have spread or can't be removed by surgery. The goal is to find the safest dose and check for…

This study tests whether a stronger chemotherapy mix (mFOLFIRINOX) works better than the standard mix (FOLFOX) for people with advanced stomach, esophageal, or gastroesophageal junction cancer that cannot be removed by surgery. Some participants also receive the immunotherapy dru…

This study tests a new drug called BNT326, given alone or with other cancer immunotherapies, in about 980 adults with advanced solid tumors that have spread or come back after prior treatment. The goal is to find the best dose and see if it is safe and effective. It is an early-s…

This early-phase study tests a new drug, ASP2998, that targets a protein called TROP2 found on many solid tumors. The drug is given alone or with standard treatments like pembrolizumab or carboplatin. The main goals are to check safety and find the right dose. About 428 adults wi…

This study tests a new drug called PYX-201 combined with pembrolizumab in people with advanced solid tumors that have not responded to other treatments. The goal is to find safe doses and see if the combination can shrink tumors. About 220 adults with certain cancers like head an…

This Phase 2 trial tests whether adding an extra drug (either SHR2554 or apatinib) to standard immunotherapy plus chemotherapy can help people with advanced gastric cancer who don't get enough benefit from current treatments. About 78 adults with stage III or IV stomach cancer wi…

This study looks at whether robotic-assisted surgery using a vessel sealer can improve outcomes for people with locally advanced stomach cancer. The vessel sealer is a tool that cuts and seals blood vessels with less heat damage than older devices. Researchers will track 300 pati…

This phase II trial tests whether adding paclitaxel directly into the abdomen, alongside standard systemic chemotherapy, is feasible for people with gastrointestinal cancers that have spread to the peritoneal lining. The study includes patients with gastric, colorectal, appendice…

This study follows 90 adults with upper stomach or gastroesophageal junction cancer who undergo proximal gastrectomy, a surgery that removes the upper part of the stomach. Researchers compare different ways to reconnect the digestive tract, such as double-tract reconstruction or …

This study tests a new drug called ivonescimab combined with standard chemotherapy (FOLFOX) in people with advanced HER2-negative stomach or esophagus cancer that has not been treated before. The goal is to see if the combination can keep the cancer from growing for at least 6 mo…

This early-phase study is testing an experimental drug called JNJ-89402638 in people with metastatic colorectal or gastric cancer that has progressed after at least two prior treatments. The trial will first find the safest dose and schedule, then test the drug alone or combined …

This early-phase study tests a new drug called STRO-004 in adults with advanced solid tumors that have not responded to standard treatments. The study has three parts: finding a safe dose of STRO-004 alone, testing that dose in more patients, and combining STRO-004 with another d…

This early-stage trial is testing a new type of radiation therapy that seeks out and attacks cancer cells while sparing healthy tissue. It's for people with advanced breast, lung, stomach, or bladder cancer who have run out of standard options. The study will check if the treatme…

This study monitors 377 South Korean patients with advanced stomach or gastroesophageal junction cancer who receive VYLOY (zolbetuximab) as part of their normal treatment. Researchers will track side effects and how long the cancer stays stable. The goal is to confirm the drug's …

This early-phase trial tests a technique called PIPAC, which turns liquid chemotherapy into a fine mist sprayed directly into the abdomen during a minimally invasive surgery. It aims to see if this approach is safe and causes fewer side effects than standard chemotherapy. The stu…

This early-phase study tests a new treatment called TNhYP218 CAR T cells for people with solid tumors that have high levels of a protein called mesothelin, including mesothelioma. Participants' own immune cells are collected, modified in a lab to better attack cancer, and then gi…

This early-stage trial is testing a new type of immune cell therapy for people with advanced cancers that have a specific protein called KK-LC-1. The cancers being studied include stomach, breast, cervical, and lung cancer. Participants will receive chemotherapy followed by a sin…

This study tests a new therapy where a person's own white blood cells are collected, genetically modified in a lab to recognize and attack cancer cells with a specific mutation (KRAS G12V), and then infused back. Participants also receive chemotherapy and a drug to boost cell act…

This Phase 1 trial tests two experimental mRNA immunotherapies, mRNA-4106 and mRNA-4200, in about 42 people with advanced solid tumors. Unlike personalized cancer vaccines made from a patient's own tumor mutations, these are off-the-shelf therapies designed to target shared antig…

This early-stage study tests a new drug (177Lu-DOTA-SNA040) that delivers radiation directly to cancer cells with a specific marker (Claudin 18.2). It is for people with advanced stomach, pancreatic, or bile duct cancers that have worsened after standard treatment. The main goals…

This study looks at whether supervised exercise can improve recovery in people who have had surgery for esophageal or gastric cancer. About 171 participants will be assigned to high-intensity interval training, low-intensity continuous training, or usual care for 8 weeks. The goa…

This study tests a personalized vaccine made from a patient's own tumor proteins, given alone or with the immunotherapy drug pembrolizumab. The goal is to see if the combination is safe and helps the immune system attack advanced solid tumors. About 132 people with various advanc…

This study tests a new drug, AZD6750, that helps the immune system fight cancer. It is for adults with advanced solid tumors like melanoma, lung, or breast cancer that have not responded to other treatments. The goal is to find the safest dose and see if it shrinks tumors when us…

This trial is testing whether combining an experimental drug called IBI343 with an immunotherapy (sintilimab) and standard chemotherapy can help people with a specific type of advanced stomach or gastroesophageal junction cancer. The study focuses on patients whose tumors have a …

This trial is testing whether adding an immunotherapy drug called adebrelimab to a two-drug combination of apatinib and albumin-bound paclitaxel can help people with advanced stomach or gastroesophageal junction cancer. The study enrolls adults whose cancer has progressed after f…

This observational study is tracking 260 adults in China with HER2-positive gastric or gastroesophageal junction cancer that is locally advanced or has spread. Participants are receiving trastuzumab deruxtecan (T-DXd) as part of their routine care, and researchers are collecting …

This study tests whether taking oral sorbitol, a common sugar alcohol, can enhance the effects of standard chemotherapy and an immunotherapy drug (tirellizumab) in people with locally advanced stomach cancer. Eighty participants will receive either sorbitol or a placebo alongside…

This study tests a new experimental drug, PF-08634404, combined with chemotherapy in people with advanced stomach, gastroesophageal junction, or esophageal cancer that has not been treated before. The trial has two parts: first checking safety and response, then comparing the new…

This study is for people with advanced gastrointestinal cancers that are growing despite immunotherapy. Researchers want to see if adding targeted radiation to one tumor can help the immune system attack other tumors throughout the body. About 28 participants will receive radiati…

This early-phase trial tests a new drug called MRG007 (ARR-217) in people with advanced solid tumors that have not responded to standard treatments. The study aims to find a safe dose and check if the drug can shrink tumors. About 405 participants with colorectal, gastric, or pan…

This phase 2 trial is testing a drug called datopotamab deruxtecan (Dato-DXd), alone or with other cancer medicines, in people with advanced or metastatic solid tumours. The study includes seven cancer types and aims to see if the drug shrinks tumours and how safe it is. Around 4…

This early-phase trial tests MGC026, a biologic drug given by IV, in 250 adults with advanced solid tumors that have not responded to standard treatments. The study has two parts: first, finding a safe dose, then expanding to see if the drug shrinks tumors. Participants receive u…

This early-phase study tests a new drug called HLX3902 in about 48 people with advanced prostate cancer or other solid tumors that have stopped responding to standard treatments. The main goal is to check the drug's safety and find the best dose. The drug is designed to help the …

This trial asks a key question: for people with advanced metastatic stomach cancer whose tumors shrink significantly after initial medical therapy (called conversion therapy), does adding radical surgery improve their chances of living longer without the disease progressing? The …

This large Phase 3 trial is testing whether a newer targeted drug, trastuzumab deruxtecan (Enhertu), combined with chemotherapy and possibly the immunotherapy pembrolizumab (Keytruda), works better than the current standard treatment for advanced HER2-positive stomach or gastroes…

This trial tests three different ways to reconnect the digestive tract after stomach cancer surgery to see which one best controls blood sugar in people who also have type 2 diabetes. Participants will be randomly assigned to one of three surgical procedures. The main goal is to …

This early-stage trial is testing an experimental immunotherapy called AB122, given alone or combined with other investigational drugs, in people with advanced solid tumors such as pancreatic, colorectal, lung, and stomach cancers. The goal is to find out which combinations are s…

This Phase 1 trial tests IDOV-Immune, a genetically engineered virus designed to infect and destroy cancer cells while boosting the immune system. It is for adults with advanced solid tumors (like colorectal, pancreatic, or lung cancer) that have not responded to standard treatme…

This early-stage study tests a new robotic surgery method that uses only one small incision to remove stomach cancer. The goal is to see if it is safe and works well. Twenty adults with stomach cancer will take part, and doctors will watch for complications during and up to 30 da…

This early-phase trial is testing an experimental drug called INBRX-106, alone or combined with the immunotherapy Keytruda, in people with advanced solid tumors (including lung, head and neck, melanoma, and others) that have stopped responding to standard treatments. The main goa…

This phase 2 trial is testing a combination of four drugs—cadonilimab, LM-302, S-1, and paclitaxel—in 40 people with a specific type of advanced stomach cancer (Claudin 18.2-positive) that has spread to the lining of the abdomen. The drugs are given through a vein and directly in…

This study tests a new drug called AZD0901, alone or with other cancer treatments, in people with advanced solid tumors that have a specific protein called CLDN18.2. The goal is to see if the drug is safe and can shrink tumors. About 224 adults with stomach, pancreatic, or bile d…

This trial is testing an experimental drug called petosemtamab (MCLA-158) in people with advanced solid tumors, including colorectal, head and neck, and lung cancers. The drug is a bispecific antibody designed to block two cancer-related proteins, EGFR and LGR5. Researchers want …

This Phase 2 trial is testing two experimental drugs (SSGJ-705 and SSGJ-612) with or without chemotherapy in 150 adults with advanced HER2-positive solid tumors, including colorectal, bladder, breast, bile duct, and stomach cancers. The goal is to see if the combination can shrin…

This study tests a combination of fruquintinib (a drug that blocks blood vessel growth to tumors) and chemotherapy (albumin-paclitaxel), with or without a PD-1 antibody, for people with advanced stomach or gastroesophageal junction cancer whose first PD-1 treatment stopped workin…

This early-stage study tests a new oral drug, MOMA-341, alone or with other treatments, in people with advanced solid tumors that have specific genetic changes (MSI-H or dMMR). The main goal is to check safety and find the best dose. About 132 adults whose cancer has not responde…

This early-stage study tests a new drug called PF-08046054/SGN-PDL1V, alone or with another drug (pembrolizumab), in people with advanced solid tumors like lung, head and neck, esophageal, breast, stomach, endometrial, pancreatic, or liver cancer. The main goals are to find safe …

This early-phase trial tests a new drug called TPD3310 in 112 people with advanced solid tumors that have not responded to standard treatments. The study aims to find a safe dose and check for early signs of tumor shrinkage. Participants receive weekly injections over 28-day cycl…

This phase 2 trial tests an experimental drug called SAR445877 in adults with advanced gastric or gastroesophageal junction cancer that has worsened after at least one prior treatment. The study includes about 30 participants and looks at whether the drug can shrink tumors. It is…

This phase 2 trial tests a drug called zanidatamab in about 200 adults with advanced HER2-positive cancers, including breast, lung, stomach, and others. Participants have already tried at least one standard treatment. The study measures how many tumors shrink or disappear. Zanida…

This trial tests a new approach for people with advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery. It combines standard chemotherapy (CAPOX) and radiation with an experimental drug called SHR-1701, which targets two proteins (PD-L1 and TGF-β) …

This study tests a new drug, BHB810, in adults with advanced stomach or gastroesophageal junction cancer that has not responded to standard treatments. The drug is given as an IV infusion every two weeks. The main goals are to check safety and find the best dose, while also seein…

This Phase 3 trial tests a new drug called BL-M05D1 against standard chemotherapy for people with advanced stomach or gastroesophageal junction cancer that has a specific marker (CLDN18.2). The study will include 438 adults who have already tried one prior treatment. The goal is …

This early-stage trial is testing a new drug called sigvotatug vedotin, alone or with other cancer medicines, in people with advanced solid tumors like lung, head and neck, and breast cancers. The study aims to find a safe dose and check for side effects. About 1,000 participants…

This study tests a new drug that delivers a tiny dose of radiation directly to cancer cells that have a specific marker called FAP. The trial involves 112 adults with advanced cancers of the pancreas, stomach, esophagus, colon, ovary, head/neck, sarcoma, or mesothelioma. First, a…

This phase II trial is testing a combination of three drugs—trastuzumab deruxtecan, capecitabine, and rilvegostomig—in people with HER2-positive, locally advanced stomach cancer that cannot be removed by surgery right away. The goal is to see if giving these drugs before and afte…

This Phase II trial is testing a combination of three drugs—zanidatamab, pembrolizumab, and chemotherapy—in 80 people with advanced stomach or esophageal cancer that has spread and tests positive for HER2 and PD-L1. The goal is to see if this triple therapy can keep the cancer fr…

This phase 2 trial tests whether adding an experimental biologic called TRK-950 to the standard combination of ramucirumab and paclitaxel helps people with advanced stomach or gastroesophageal junction cancer. Participants receive either the standard two-drug regimen or the stand…

This Phase 3 trial tests whether a combination of two immunotherapy drugs (botensilimab and balstilimab) can help people with advanced stomach cancer live longer compared to standard treatment. The study includes 132 adults whose tumors have a specific genetic marker (MSI-H/dMMR)…

This early-stage trial tests an experimental drug called SAR445877, alone or with other cancer drugs, in adults with advanced solid tumors that have spread or cannot be removed. The study has two parts: first, finding a safe dose, and second, checking if the drug shrinks tumors. …

This phase 2 trial tests whether delivering FOLFOX chemotherapy directly into the arteries feeding the tumor can help control advanced stomach or gastroesophageal junction cancer. The study includes 31 adults who cannot have surgery due to frailty or other health issues. The main…

This trial investigates whether using a device that sends mild electrical pulses to the thigh muscles (neuromuscular electrical stimulation, or NMES) can prevent muscle loss and weakness after abdominal surgery for colorectal or gastric cancer. Some participants will also receive…

This early-stage study tests a new drug called BAL0891, given alone or with chemotherapy or immunotherapy, in people with advanced solid tumors or acute myeloid leukemia (AML) that has come back or not responded to treatment. The main goals are to find a safe dose and check for s…

This early-phase study tests an experimental drug called OKN4395, taken as a pill, alone or together with the immunotherapy pembrolizumab. The goal is to find a safe dose and see if the combination can shrink tumors in people with advanced solid cancers like lung, colorectal, sto…

This early-stage trial is testing a new drug called THE-0504 in 30 adults with advanced solid tumors, including lung, colon, stomach, breast, and pancreatic cancers. The main goal is to see if the drug is safe and to find the best dose. Researchers will also watch for any signs t…

This early-stage trial is testing an experimental oral drug called EXS74539 (REC-4539) in about 40 people with various solid tumors, including lung, prostate, ovarian, and breast cancers. The main goal is to check the drug's safety, find the right dose, and see how the body proce…

This study tests whether adding the supplement taurine to a standard treatment (immunotherapy drug serplulimab plus chemotherapy) can improve outcomes for people with locally advanced stomach or gastroesophageal junction cancer. About 96 adults whose tumors have a specific marker…

This study tests a new drug called IAH0968, given alone or with chemotherapy (CAPEOX), in people with advanced HER2-positive stomach cancer or other solid tumors. The goal is to see if the combination is safe and helps slow cancer growth better than standard treatment. About 574 …

This program provides the experimental drug ulixertinib to people with advanced solid tumors that have certain gene mutations (MAPK pathway). It is for patients who have not responded well to or have run out of standard treatments. The goal is to control the disease and possibly …

This study tests whether adding the drug cadonilimab to standard chemotherapy (FLOT) helps people with a certain type of stomach or gastroesophageal junction cancer that can be removed with surgery. About 37 adults will receive the combination before and after surgery. The goal i…

This study tests a new treatment for stomach cancer that has spread to the lining of the belly (peritoneal metastases). About 55 patients will receive chemotherapy directly into the abdomen along with standard intravenous chemotherapy, and possibly immunotherapy or targeted thera…

This study is testing a new way to give radiation therapy (called PULSAR) along with standard chemotherapy and immunotherapy for people with advanced stomach cancer that cannot be removed with surgery. The radiation is given in high doses every few weeks, tailored to each patient…

This early-phase trial tests a new cell therapy called UCLH80-1 in 36 people with advanced solid tumors (colorectal, gastric, pancreatic, and bile duct cancers) that have not responded to standard treatments. The therapy uses specially engineered immune cells to target a protein …

This study tests an experimental drug called SHR-A1904 in 83 people with advanced solid tumors, including stomach and pancreatic cancers that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tum…

This early-phase trial is testing a new type of cell therapy called p95HER2.CAR-TECH2Me for people with advanced HER2-positive breast, gastric, or endometrial cancers that have spread. The treatment uses a patient's own immune cells, which are modified in a lab to better recogniz…

This study is testing whether giving a protein-enriched intravenous nutrition formula helps patients recover better after surgery for stomach cancer. About 110 adults having stomach cancer surgery will be randomly assigned to receive either the protein-enriched nutrition or stand…

This early-phase trial is testing an experimental drug called DA-3501 in 51 adults with advanced stomach, gastro-esophageal junction, or pancreatic cancers that have a specific protein (CLDN18.2). Participants receive the drug by IV once every three weeks. The main goals are to f…

This study tests a new drug called BOLD-100 combined with standard FOLFOX chemotherapy in people with advanced colorectal, pancreatic, stomach, or bile duct cancers that have spread or cannot be removed. The goal is to see if the combination is safe and helps control tumor growth…

This phase 3 trial tests whether adding the immunotherapy drug adebrelimab to standard chemotherapy (S-1 and oxaliplatin) works better than chemo alone for people with stomach or gastroesophageal junction cancer that can be surgically removed. About 874 participants will receive …

This phase 2 trial is testing whether a combination of immunotherapy drugs (sintilimab, IBI310, and lenvatinib) can help people with non-metastatic dMMR/MSI-H stomach or colon cancers avoid radical surgery. About 34 participants will receive up to 24 weeks of treatment, and those…

This Phase 2 trial tests whether adding the experimental drug givastomig to standard immunotherapy and chemotherapy can help people with advanced stomach or esophageal cancer live longer without their cancer growing. About 180 adults whose tumors have certain proteins (CLDN18.2 a…

This Phase 2 trial is testing several new drug combinations in people with advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery or has spread. The study aims to see if these combinations can shrink tumors and keep them from growing for at least 6…

This study tests a new combination of drugs (LM-108 and toripalimab) against standard chemotherapy for people with advanced stomach cancer that has gotten worse after first treatment. About 400 adults with a specific marker (CCR8-positive) will be randomly assigned to receive eit…

This study tests IKS014, a drug designed to seek out and destroy HER2-positive cancer cells, in people with advanced solid tumors like breast, stomach, and gastroesophageal cancers. The main goals are to find the safest dose and check for early signs of tumor shrinkage. About 165…

This study tests a new drug called MDX2001 in people with advanced solid tumors that have spread. The main goals are to check the drug's safety and see if it can shrink tumors. About 285 adults with various cancers like lung, breast, or colon cancer will take part. This is an ear…

This study tests a new method called PIPAC, which sprays chemotherapy directly into the abdomen as a fine mist. It is for people with stomach, pancreas, or colorectal cancer that has spread to the lining of the abdomen. The goal is to see if this approach can control the cancer a…

This early-phase trial is testing a new targeted drug called CA-4948 combined with standard chemotherapy and immunotherapy for people with advanced stomach, esophageal, or gastroesophageal junction cancer that cannot be removed by surgery. The study will enroll 42 participants an…

This study tests a new drug called ZGGS34 in people with advanced solid tumors that have not responded to standard treatments. The trial has two parts: first, finding a safe dose, and second, testing how well the drug works alone or with chemotherapy in patients whose tumors have…

This study compares two types of stomach surgery (partial vs. total removal) for people with advanced upper gastric cancer who have already received chemotherapy combined with an immunotherapy drug. The goal is to see which surgery leads to better long-term outcomes, such as prev…

This study tests a combination of drugs (LM-302, S-1, and intraperitoneal paclitaxel) with or without another drug (cadonilimab) in people with a specific type of advanced stomach cancer (Claudin 18.2-positive) that has spread to the lining of the abdomen. The goal is to see if t…

This early-stage trial tests an experimental oral drug called NKT3964 in adults with advanced or metastatic solid tumors that have not responded to standard treatments. The drug works by degrading a protein (CDK2) that helps cancer cells grow. The study has two parts: first, find…

This study tests whether a 3-day low-leucine diet can make chemotherapy and immunotherapy work better for people with advanced stomach cancer. Researchers believe the diet may activate immune cells in the tumor. The trial involves 73 participants and will measure tumor shrinkage …

This Phase 1 trial is testing an oral drug called AUR107 in 50 adults with advanced solid tumors that have come back after prior treatment. The study aims to find a safe dose and understand how the drug moves through the body. It is the first time AUR107 is being tested in humans…

This study tests whether a short-term diet low in leucine (an amino acid) can make standard chemo-immunotherapy work better for stomach cancer patients. About 108 people will follow the diet for 3 days during each treatment cycle. Researchers will check if this approach improves …

This study is for people with esophageal or stomach cancer that has spread to 3 or fewer places in the body. It compares standard chemotherapy alone to chemotherapy plus radiation or surgery to the main tumor and those spots. The goal is to see if adding local treatment helps peo…

This study tests a two-step treatment for people with advanced liver cancer (hepatocellular carcinoma) or metastatic stomach cancer that has worsened despite prior immunotherapy. First, doctors deliver a drug called tirapazamine directly into the liver tumor through a procedure c…

This early-stage trial is testing a new drug called TGW101 in people with advanced solid tumors that have not responded to other treatments. TGW101 is given in two parts: an antibody-drug conjugate and a chemical trigger that activates it. The main goal is to check safety and fin…

This study tests a new drug called EIK1005, alone or with another drug (pembrolizumab), in people with advanced solid tumors that have not responded to other treatments. The goal is to find a safe dose and see if the drug shrinks tumors. About 160 adults with certain cancer types…

This study compares two types of surgery for patients with early-stage stomach cancer near the esophagus. One method adds a procedure to widen the stomach outlet, which may help prevent severe acid reflux after surgery. The trial will track reflux, quality of life, and complicati…

This study tests whether using a reinforcement patch on surgical staplers can lower the risk of leaks and other complications after stomach cancer surgery. About 382 patients will be randomly assigned to receive either the reinforced stapler or a standard stapler during their ope…

This early-stage trial is testing a new daily oral medication called ETX-19477 in about 120 adults with advanced solid tumors, including breast, ovarian, prostate, and other cancers. The drug blocks a protein called PARG to interfere with cancer cells' ability to repair themselve…

This early-stage trial is testing a virus called IVX037, which is injected directly into tumours to kill cancer cells. It is being studied alone and combined with an immunotherapy drug (sintilimab) in people with advanced colorectal, gastric, or ovarian cancers that have stopped …

This early-stage trial is testing a new type of immune cell therapy called armored dendritic cells in 8 people with solid cancers like pancreatic or colorectal cancer. Participants have already had surgery and at least 4 rounds of chemotherapy. The goal is to see if the treatment…

This study tests whether adding an immune-boosting drug (thymosin alpha 1) to standard chemo-immunotherapy can improve outcomes for people with stage III gastroesophageal junction cancer. About 48 participants will receive either the standard treatment or the standard plus thymos…

This study tests whether adding the targeted drug disitamab vedotin to standard chemotherapy (SOX) after surgery can help prevent stomach cancer from coming back in people with HER2-positive stage III disease. About 124 adults who had complete tumor removal with extensive lymph n…

This study tests a combination of two drugs, carilizumab and albumin paclitaxel, as a second treatment for people with advanced stomach cancer. It includes 40 adults aged 18-75 who have already tried one prior treatment, with or without immunotherapy. The goal is to see if this c…

This phase 3 trial tests whether adding heated chemotherapy (HIPEC) directly into the abdomen after stomach cancer surgery can help patients live longer and prevent cancer from coming back in the belly. About 616 adults with advanced stomach cancer will be split into two groups: …

This early-stage study tests an experimental drug called TJ033721 (givastomig) in people with advanced or metastatic solid tumors that have stopped responding to standard treatments. The main goals are to check the drug's safety, find the right dose, and see how the body processe…

This study tests a combination of two drugs, MCLA-129 and ensartinib, in people with advanced solid tumors that cannot be cured. The drugs work by blocking certain proteins that help cancer grow. The trial has two phases: first to find the safest dose, then to see if the combo sh…

This study tests whether adding an immune-boosting drug (thymalfasin) to standard chemotherapy and immunotherapy can help shrink stage III stomach or gastroesophageal junction cancer before surgery. About 30 adults aged 18-75 will receive the combination, then have their tumor ti…

This Phase 3 trial tests whether adding an experimental antibody (HLX22) to standard treatment (trastuzumab plus chemotherapy) works better for people with advanced HER2-positive stomach or gastroesophageal junction cancer. About 550 participants will be randomly assigned to rece…

This early-stage trial tests a new treatment for advanced gastric cancer that has not responded to standard therapies. It combines a special vaccine made from the patient's own tumor markers (neoantigens) with immune cells trained to attack the cancer. The main goals are to see i…

This study tests an experimental drug called AZD5863 in adults with advanced stomach, gastro-esophageal junction, pancreatic, or esophageal cancers that have spread. The drug is a bispecific antibody designed to bring immune cells close to cancer cells to attack them. The main go…

This study tests a new combination of drugs for people with advanced stomach cancer that got worse after initial immunotherapy. The treatment includes a targeted therapy (fruquintinib), chemotherapy (nab-paclitaxel), and a new immunotherapy (iparomlimab and tuvonralimab). The goa…

This study tests whether a new type of radiation machine that uses MRI to guide treatment is safe and practical for people with gastric, breast, or other cancers. About 70 adults will receive radiation guided by real-time MRI, sometimes with chemotherapy. The goal is to see if th…

This study looks at different drug combinations for people with advanced stomach or gastroesophageal junction cancer that has not responded to first-line treatment. Researchers will observe 250 participants receiving albumin-bound paclitaxel-based regimens, including immune check…

This early-stage trial tests a new combination treatment for people with advanced HER2-positive solid tumors (like breast, lung, or stomach cancer). Participants receive an injection of a special virus directly into one tumor to help the immune system attack cancer, followed by a…

This early-phase study tests a new drug called SH009 in people with advanced solid tumors (like liver, lung, breast, or stomach cancer) that have not responded to standard treatments. The main goals are to see if the drug shrinks tumors and to check its safety. About 150 adults w…

This phase 3 trial is testing whether a personalized program of supplements (vitamin D, mushroom extract, fish oil, probiotics, and whey protein) plus lifestyle coaching can improve recovery and quality of life for people undergoing surgery for lung, stomach, or esophageal cancer…

This study tests a new treatment called CHM-2101 for people with advanced gastrointestinal cancers (stomach, colon, rectal, or neuroendocrine tumors) that have stopped responding to standard therapies. The treatment uses the patient's own immune cells, which are modified in a lab…

This early-phase trial is testing a new drug called BDC-4182 in people with advanced gastric or gastroesophageal cancer that has spread or cannot be removed. The drug is designed to attach to a protein on cancer cells and stimulate the immune system to attack them. The study will…

This early-phase trial is testing an experimental drug called TH9619 in about 43 adults with advanced solid tumors, including colorectal, head and neck, lung, and gastric cancers. The main goal is to check the drug's safety and find the right dose. Participants must have already …

This study tests a new drug called TCC1727 combined with other medicines (benmelstobart, olaparib, or topotecan) in people with advanced solid tumors, including lung, stomach, endometrial cancer, and melanoma. The goal is to find the safest dose and see if the combination helps s…

This early-stage trial is testing a new drug, BM230, in people with advanced solid tumors, especially those linked to HER2. The study has two parts: first, finding the safest dose, then expanding to see how well it works. About 123 participants will be enrolled worldwide.

This phase 3 trial tests whether a chemotherapy combination of oxaliplatin plus S-1 works as well as or better than docetaxel plus S-1 for stage III gastric cancer patients who have had surgery. About 387 adults aged 18 to 80 will be randomly assigned to one of the two treatments…

This early-phase study tests a new treatment called PTC13, which uses specially engineered immune cells (CAR-T cells) to attack cancer cells that have a protein called CEA. The study includes 18 adults with advanced colorectal, stomach, pancreatic, or other solid tumors that have…

This study tests a new drug called 3H-10000, which is an antibody-drug conjugate designed to target and kill cancer cells. It is for people with advanced lung or stomach cancer that cannot be removed by surgery or has spread. The trial will enroll 170 participants to find the saf…

This study is for people with stomach cancer that has spread to a few other places in the body. It tests whether adding surgery and other local treatments to a combination of immunotherapy and chemotherapy helps people live longer without the cancer getting worse. About 84 adults…

This study tests a combination of two drugs, savolitinib and durvalumab, in people with advanced stomach cancer that has a specific gene change called MET amplification. Participants must have already tried at least one chemotherapy that didn't work. The goal is to see if this co…

This study tests whether combining the targeted drug cabozantinib with immunotherapy drugs (durvalumab, with or without tremelimumab) is safe and effective for people with advanced stomach, esophageal, liver, or colorectal cancer. About 117 adults with stage 3 or 4 disease that c…

This study tests whether a combination of two drugs (camrelizumab and apatinib) can help people with advanced stomach or gastroesophageal junction cancer live longer compared to standard chemotherapy. The trial includes 550 adults whose cancer progressed after first-line platinum…

This study looks at whether giving heated chemotherapy directly into the abdomen during surgery can help prevent stomach cancer from coming back. About 200 adults with advanced stomach cancer that has spread to the lining of the abdomen will receive the treatment. The goal is to …

This early-stage study tests an experimental oral drug called DPTX3186 in 40 adults with advanced solid tumors (like colorectal, gastric, lung, or triple-negative breast cancer) that are linked to a specific cell signal called Wnt. These participants have no other approved treatm…

This study tests a combination of three drugs (fruquintinib, trastuzumab, and chemotherapy) as a first treatment for people with HER2-positive advanced stomach or gastroesophageal junction cancer. The goal is to see if the combo is safe and can shrink tumors or slow cancer growth…

This Phase 2 study is testing several new drug combinations for people with stomach or gastroesophageal junction cancer who have not had prior treatment. The combinations include an immunotherapy drug (adebrelimab) plus targeted drugs (SHR-A1811, SHR-A1904, or SHR-8068) and chemo…

This early-stage trial is testing a new drug called DR-0202, a bispecific antibody, in people with advanced solid tumors (such as breast, lung, and pancreatic cancers) that have not responded to at least two prior treatments. The study aims to find a safe dose and see if the drug…

This study tests a new combination of two experimental drugs (iparomlimab and tuvonralimab, together called QL1706) plus standard chemotherapy in people with advanced stomach or gastroesophageal junction cancer that hasn't been treated before. The goal is to see if this combo can…

This study tests a new robotic system with an extra arm for stomach cancer surgery. Ten adults with stomach cancer will have their surgery using this robot. The goal is to see if the robot is safe and can complete the surgery without switching to other methods.

This study tests a combination of three drugs (SHR-1701, rivoceranib, and possibly SHR-2554) in 40 adults with advanced stomach or gastroesophageal junction cancer that worsened after or could not tolerate first-line immunotherapy. The goal is to see if the new combo can shrink t…

This early-phase trial tests an oncolytic virus (IDOV-SAFE) in about 89 people with advanced digestive cancers, like colorectal or stomach cancer, that have not responded to standard treatments. The virus is designed to infect and kill cancer cells. Some participants may also rec…

This study tests whether taking glutamine by mouth can help gastric cancer patients regain muscle and improve nutrition after having their stomach removed. About 120 adults who had stomach cancer surgery will take glutamine supplements and be monitored for changes in muscle size,…

This early-stage study tests whether combining two drugs (sacituzumab govitecan and capecitabine) is safe for people with advanced gastrointestinal cancers that have stopped responding to standard treatments. About 20 adults with stomach, colorectal, or pancreatic cancer will tak…

This study tests a new drug called LM-108, which clears certain immune cells from tumors, combined with standard chemotherapy and another immunotherapy. The goal is to see if this mix is safe and can slow or shrink advanced solid tumors. About 194 adults with advanced cancers wil…

This study tests a 'screen and treat' approach for H. pylori infection in 14-18 year olds in Chile, where stomach cancer rates are high. Researchers will screen up to 1000 teens and randomly assign 210 persistently infected participants to receive antibiotics or no treatment. The…

This early-phase trial tests a new drug called MT-4561 in about 27 people with advanced solid tumors (like lung, breast, or pancreatic cancer) who have no standard options left. The main goals are to find a safe dose and see if the drug can shrink tumors. It is a first-in-human s…

This study tests whether adding a probiotic called Saccharomyces boulardii to a standard antibiotic cocktail helps clear Helicobacter pylori infections that didn't respond to earlier treatments. About 1,248 adults who have failed prior H. pylori therapy will be randomly assigned …

This trial tests capmatinib, a drug already approved for certain lung cancers, in adults with rare cancers that have specific MET gene changes. About 30 participants will receive the drug to see if it can shrink tumors or stop them from growing for at least 24 weeks. The goal is …

This study compares standard chemotherapy alone versus chemotherapy plus a special procedure called PIPAC (pressurized intraperitoneal aerosol chemotherapy) for people with stomach cancer that has spread to the lining of the abdomen. About 106 adults aged 18-75 will take part. Th…

This study tests a combination of three drugs—lenvatinib, nivolumab, and chemotherapy—in people with advanced stomach cancer that has spread to the lining of the abdomen and caused fluid buildup (ascites). The goal is to see if this triple therapy can shrink tumors and help patie…

This early-phase trial is testing a new method of delivering chemotherapy directly into the abdomen as a fine mist under pressure (PIPAC) for people with stomach cancer that has spread to the lining of the belly. The study combines this misted chemotherapy (nab-paclitaxel) with s…

This study tests two drugs, avutometinib and defactinib, in people with a specific type of advanced stomach cancer called diffuse gastric cancer. The goal is to see if the combination can slow tumor growth or shrink tumors. About 27 adults who have already tried at least one stan…

This Phase I trial tests adaptive stereotactic body radiation (SBRT) for people with cancer that has spread to the abdomen or pelvis. The goal is to safely deliver higher radiation doses to tumors while keeping severe side effects under 10%. Thirty participants will receive this …

This study tests a new treatment called RAK cell therapy, made from human umbilical cord blood, for people with advanced stomach cancer that has spread or come back after standard treatment. The goal is to see if it can help patients live longer and keep the cancer from growing, …

This program provides early access to an experimental drug called AVM0703 for people with various solid tumors and blood cancers, including hard-to-treat types like glioblastoma and metastatic breast cancer. It is available to patients in the US whose doctor requests it. So far, …

This early-stage study is testing a new treatment called CEA-targeted CAR-T cells for people with advanced solid tumors like lung, stomach, colon, rectal, esophageal, or pancreatic cancer that have not responded to standard therapies. The treatment uses a patient's own immune cel…

This early-phase trial tests a personalized vaccine made from a patient's own tumor cells or donor cells. The cells are modified and killed in the lab, then injected under the skin to train the immune system to attack the cancer. The study includes 50 adults with metastatic melan…

This study tests whether a combination of three drugs (RC48, sintilimab, and SOX) can shrink advanced stomach cancer enough to allow surgical removal. It includes 30 adults with a specific type of HER2-positive cancer who have not had prior treatment. The goal is to see how many …

This phase II study is testing whether a new drug called SI-B003, alone or combined with BL-B01D1 or a PD-1 antibody, can shrink tumors in people with advanced esophageal, gastric, or colorectal cancer. About 376 participants will receive the treatments intravenously every three …

This phase 2 trial tests whether adding a daily pill containing a specific gut bacterium (EXL01) to standard immunotherapy (nivolumab) and chemotherapy (FOLFOX) can shrink tumors better than the drugs alone in people with advanced gastric cancer. About 120 participants will be ra…

This study compares two types of surgery for advanced stomach cancer: keyhole (laparoscopic) and open total gastrectomy. About 1,018 patients will be randomly assigned to one of the two procedures. The main goal is to see if keyhole surgery offers similar long-term survival with …

This study tests two AI platforms to personalize cancer treatment for people with solid tumors like gastrointestinal or breast cancer. First, a platform called QPOP analyzes a patient's tumor sample to find the best drug combination. Then, another AI called CURATE.AI adjusts the …

This early-phase study tests a new drug called BL-M17D1 in 20 people with advanced HER2-positive gastrointestinal cancers (like stomach, pancreas, or colon cancer) or other solid tumors. The main goals are to check safety, find the right dose, and get a first look at whether the …

This phase 2 trial tests whether adding radiotherapy and two immunotherapy drugs (iparomlimab and tuvonralimab) to standard chemotherapy can improve outcomes for people with resectable stomach or gastroesophageal junction cancer. About 40 participants will be randomly assigned to…

This Phase 2 trial is testing whether a new targeted drug called SHR2554, taken as a tablet, can be safely combined with other anti-cancer injections to treat advanced stomach or gastroesophageal junction cancer. The study will enroll 351 adults whose cancer has spread or cannot …

This early-stage trial tests the safety and effectiveness of a new drug called JR8603 in people with advanced solid tumors, including stomach and colorectal cancers, who have not responded to standard treatments. Participants receive JR8603 by IV infusion three times per month. T…

This study tests a combination of two drugs—glumetinib (a targeted therapy) and a special form of docetaxel (chemotherapy)—in people with advanced stomach cancer or other solid tumors that have a specific genetic marker called MET overexpression. The trial has two stages: first t…

This early-stage trial tests a new drug called NX-1607 in adults with advanced cancers that have not responded to standard treatments. The study aims to find a safe dose and see if the drug can shrink tumors. It includes people with several cancer types, such as ovarian, lung, an…

This early-phase trial is testing a new drug called SON-DP in 96 adults with advanced solid tumors, specifically liver and gastric cancers. The main goals are to check the drug's safety, find the right dose, and see if it can control the disease. Participants receive SON-DP throu…

Researchers at Ruijin Hospital are testing two PET imaging tracers, FAPI and Grazytracer, to see if they can predict how well advanced gastric cancer responds to preoperative immunotherapy. The study enrolls 120 adults with resectable or advanced gastric cancer. Participants rece…

This study is testing a new type of PET/CT scan called [¹⁸F]FAPI-74 to see if it can better detect when stomach or esophageal cancer has spread to other parts of the body. About 200 adults with these cancers will receive one dose of the scan tracer and be followed for up to 3 mon…

This phase 2 study tests whether a radioactive tracer called [68Ga]BED003 can improve PET/CT scans for detecting cancer in the peritoneum (the lining of the abdomen). The trial includes adults with colorectal, ovarian, gastric, pancreatic, or a type of breast cancer. Researchers …

Researchers are testing whether measuring aneuploidy (abnormal chromosome numbers) in cell-free DNA from peritoneal lavage fluid can improve the detection of gastric cancer that has spread to the abdominal lining. The study enrolls adults with gastric cancer and non-cancer contro…

Researchers at Xijing Hospital are testing whether changes in blood methylation levels, a type of genetic marker, can reflect how well stomach cancer treatment is working. The study will enroll 150 adults with gastric or gastroesophageal junction cancer who have not yet had surge…

This study aims to see if testing stool samples for multiple markers can accurately screen for stomach and colorectal cancers. About 5,000 adults scheduled for endoscopy will provide a stool sample before the procedure and be followed for two years. The goal is to develop a non-i…

This study tests a radioactive compound called IR199 in people with gastric or pancreatic cancer that has a specific marker, Claudin 18.2. The goal is to see how the compound spreads through the body and how much radiation reaches tumors and healthy organs. Ten participants recei…

This study is developing a blood test that looks for tiny genetic molecules called miRNAs, which can signal the presence of several gastrointestinal cancers like liver, pancreatic, and colorectal cancer. Researchers will analyze blood samples from 1,000 adults—half with cancer an…

This study tests whether artificial intelligence (AI) can help doctors better detect H. pylori infection and precancerous stomach changes during routine endoscopy. The goal is to see if AI assistance can reduce deaths from stomach cancer. The trial will enroll 6,000 adults aged 2…

This study is testing a blood test that looks for tiny bits of cancer DNA (ctDNA) in people with esophageal, gastric, or pancreatic cancer. The goal is to see if it can find signs of cancer coming back or getting worse earlier than current methods. About 34 participants will give…

This study tests a new radioactive tracer called [18F]FPyQCP for PET scans to see if it can better detect several cancers, including colorectal, ovarian, gastric, breast, and pancreatic. About 71 adults with these cancers will receive the tracer and have a PET/CT scan. The goal i…

This study tests a new PET/CT scan using a radioactive tracer called GEH300079 to detect peritoneal carcinomatosis—cancer that has spread to the lining of the abdomen—in people with colorectal, stomach, ovarian, or pancreatic cancer. About 175 adults with known or suspected sprea…

This study tests whether an artificial intelligence (AI) tool can help radiologists more accurately determine the stage of stomach cancer from CT scans. Fifty-four radiologists will review 60 scans each, first without AI help and then with AI assistance, to see if the AI improves…

This study tests whether a new imaging agent called [18F]FAPI-74 can find certain cancers as well as or better than the standard PET tracer. About 320 adults with one of 11 cancer types (including pancreatic, liver, ovarian, and lung cancers) will receive both tracers and have th…

This study is developing an artificial intelligence (AI) system to predict how well gastric cancer will respond to chemotherapy and immunotherapy given before surgery. Researchers will collect data from 2,000 patients with locally advanced gastric cancer. The AI will analyze stan…

This study is testing an artificial intelligence tool called DeepComp that uses CT scans and patient data to predict which stomach cancer patients are at high risk for major complications after surgery. Researchers will enroll 500 patients across five medical centers and compare …

This early-stage trial is testing a new radioactive tracer called 68Ga-FXX489 (NNS309) for PET/CT scans. The goal is to see if it can safely and accurately detect tumors and their spread in 30 adults with suspected cancer. Researchers will measure how the tracer moves through the…

This study explores whether a magnetic resonance spectroscopy (MRS) scan of the thigh can predict a patient's fitness for major cancer surgery, as an alternative to the standard cardiopulmonary exercise test (CPET). Researchers will compare fat levels in thigh muscles from the MR…

This study looks at whether the things people buy at stores—like pain relievers or digestive aids—could be early warning signs of cancer. Researchers will compare the shopping habits of 2900 people, some diagnosed with cancer and some not, to see if certain purchases happen more …

This study is testing a new way to screen for stomach cancer using a stool sample and a simple questionnaire. Researchers will enroll 15,000 people aged 40 and older to see if the fecal DNA test can find cancer earlier than current methods. Participants will provide a stool sampl…

This study aims to see if certain chemicals (oncometabolites) in a person's breath and blood can spot early-stage gastro-esophageal cancer. Researchers will compare samples from 1,000 people, including those with cancer, those with Barrett's esophagus (a precancerous condition), …

This study is testing a blood test that looks for DNA signals from 20 different cancers, including lung, breast, and colon cancer. Researchers will see if the test can find cancer early, detect any cancer left after treatment, and catch a relapse before it shows up on scans. The …

This study tests a special dye and imaging system to help surgeons see colorectal, pancreatic, esophageal, and stomach cancers during surgery. About 66 adults scheduled for cancer surgery will receive the dye, and the imaging system will check if it lights up cancer tissue. The g…

This study is testing a new type of PET scan that uses special probes to highlight digestive system cancers, such as stomach, liver, colon, and pancreatic cancers. Researchers will enroll 400 adults to see how well this imaging method finds tumors and tracks their response to tre…

This study tests a new PET imaging probe that targets a protein called CLDN18.2, found in some stomach, pancreatic, bile duct, and esophageal cancers. Researchers will scan 56 people (patients and healthy volunteers) to see if the scan can accurately detect tumors and guide treat…

This study tests a special fluorescent dye that attaches to cancer cells to help doctors see if lymph nodes contain cancer during surgery for early gastric cancer. About 47 people with early gastric cancer will have their removed lymph nodes examined with this probe. The goal is …

This study is testing a simple, less invasive way to detect early signs of Barrett's esophagus, esophageal cancer, and stomach cancer. Participants swallow a capsule attached to a string, which expands into a sponge in the stomach to collect cell samples. Researchers then look fo…

This study is testing an artificial intelligence system that analyzes routine contrast-enhanced CT scans to detect stomach cancer and determine its stage (how far it has spread). The goal is to help doctors decide the best treatment, such as whether surgery is needed and how much…

This study tests a new imaging technique called iPPG, which uses light to measure blood flow, against the standard method using a green dye (ICG) during gastrointestinal surgery. The goal is to see if iPPG can predict and prevent anastomotic leaks—a serious complication where the…

This study tests whether a dye called pafolacianine (CYTALUX™) can make cancer cells glow under near-infrared light during surgery. Fifteen adults with gastric, esophageal, or appendiceal cancer will receive the dye before standard surgery. Surgeons will use a special camera to l…

This phase 2 trial tests whether riluzole, a drug already approved for ALS, can prevent the cognitive problems (often called 'chemo brain') that many cancer patients face during chemotherapy. The study will enroll 24 adults with various cancers who are about to start chemotherapy…

This program offers a simple breath test to 50,000 Aboriginal people in remote Taiwan to detect H. pylori, a bacteria linked to stomach cancer. Those who test positive receive treatment to wipe out the infection. The goal is to see if this approach lowers cancer rates in a high-r…

This study looks at whether a prehabilitation program—including physical therapy, dietary advice, and emotional support—given before major cancer surgery can reduce deaths and serious complications within 30 days after the operation. About 180 adults with cancers of the pancreas,…

This trial compares a new surgery called partial stomach-partitioning gastrojejunostomy (SPGJ) to the standard surgery for relieving stomach blockage in advanced gastric cancer. The goal is to see which surgery better helps patients eat normally, with fewer complications like del…

Cancer treatment often leaves patients with a deep, lasting tiredness that few treatments can fix. Researchers are testing whether guarana, a caffeine-rich Amazonian plant, can reduce that fatigue and improve daily life. The study gives 60 people with breast, lung, colorectal, ce…

This phase II trial tests whether a standardized acupuncture protocol can reduce peripheral neuropathy, a common and often lasting side effect of oxaliplatin chemotherapy. Participants are adults with gastrointestinal solid tumors who stopped oxaliplatin-based treatment and still…

This study compares two types of nerve blocks—coeliac plexus block and splanchnic nerve block—to see which one reduces pain better in adults with upper abdominal cancer. Forty-four participants will receive one of the procedures and be monitored for pain, opioid use, and quality …

This study tests whether cancer patients can complete a supervised exercise program from home using video calls. The program includes resistance training with dumbbells and aerobic exercise. Researchers want to see if this approach is practical and helps patients maintain functio…

This study tests a surgical technique called a jejunal pouch in 26 adults who need their entire stomach removed due to cancer or a high-risk gene mutation. The pouch is created from a section of the small intestine to replace the stomach's reservoir function. The goal is to reduc…

This study tests whether riluzole, a drug already used for ALS, can help cancer survivors who struggle with memory, focus, and mental clarity after treatment — a condition called cancer-related cognitive impairment. Researchers will measure changes in a brain protein called BDNF …

This trial tests whether a smartphone-based program combining exercise, nutrition advice, and psychological support can reduce complications and improve recovery in 186 gastric cancer patients undergoing neoadjuvant therapy and surgery. Participants follow the program from before…

This study tests whether a program of physical therapy, nutritional planning, and psychological support before and after surgery can help patients with locally advanced esophageal, gastroesophageal junction, or stomach cancer recover better. Sixty participants will follow the pro…

This study tests whether taking omega-3 fish oil capsules and doing simple resistance exercises with elastic bands can help cancer patients maintain muscle mass and strength. It involves 288 adults with various cancers who are at risk of muscle wasting. The goal is to improve phy…

This early-stage trial tests a new drug called GB18 in 18-36 cancer patients who are losing weight and appetite due to their illness (cachexia). The drug is given as a shot under the skin. The main goal is to check safety, but researchers will also see if it helps patients gain w…

This study looks at two different ways to reconnect the stomach after surgery for upper stomach cancer. The goal is to see which method causes less acid reflux and helps patients feel better and eat better. About 52 adults with early-stage stomach cancer will take part across six…

This study is testing whether a low dose of olanzapine, a drug usually used for mental health conditions, can prevent or treat the loss of appetite and weight that often happens in cancer patients receiving chemotherapy. About 100 adults with stomach or ovarian cancer will take t…

This study tests whether a high-protein nutrition plan combined with resistance exercises, started weeks before surgery and continued for 24 weeks after, can help older adults with cancer preserve their physical function. The trial enrolls Veterans aged 55 and older with certain …

This study compares two common surgical techniques used to reconnect the digestive tract after partial stomach removal for gastric cancer: Billroth II (one connection) and Roux-en-Y (two connections). The goal is to see which method leads to better quality of life one year after …

This pilot study tests whether brodalumab, a drug used for autoimmune conditions like psoriasis, can safely reduce immune-related side effects caused by cancer immunotherapy. About 11 adults with advanced solid tumors who developed these side effects will receive brodalumab injec…

This study tests a personalized rehabilitation program for people recovering from surgery for esophageal or gastric cancer. Participants will receive a structured assessment of their physical, psychological, and social needs, followed by evidence-based support. The goal is to imp…

This study tests whether a high-flow nasal cannula (a device that delivers warm, moist oxygen) can prevent low oxygen levels during sedated gastrointestinal endoscopy in people at high risk for obstructive sleep apnea. About 600 adults with a STOP-Bang score of 5 or higher will b…

This study tests a software tool called myDIET that helps manage nutrition in people with stomach or esophageal junction cancer who are scheduled for surgery. Patients answer simple questions about eating, weight, and symptoms, and the tool gives tailored advice. The goal is to s…

This study looks at whether people with certain cancers prefer getting their immune therapy as a shot under the skin (subcutaneous) or through a needle in a vein (intravenous). About 880 adults who are already eligible for standard treatments like nivolumab or pembrolizumab will …

This study compares a new nerve block (EOIB) to a standard combination of blocks for pain after laparoscopic stomach removal. 100 adults undergoing this surgery will be randomly assigned to receive one of the two blocks. The goal is to see if the new block is as good at reducing …

This study tests a newer nerve block technique (external oblique intercostal block) against a standard one (erector spinae plane block) for pain after laparoscopic stomach removal. About 184 adults having this surgery will be randomly assigned to one of the two blocks. The main g…

This study tests whether a new device that combines a bite block, oxygen tube, and airway support can prevent dangerously low oxygen levels in severely obese patients during sedated endoscopy. About 410 adults with a BMI of 35 or higher will be randomly assigned to receive either…

This study compares two minimally invasive nerve block techniques to relieve severe upper abdominal cancer pain that hasn't responded to standard treatments. About 56 adults with stomach, pancreatic, or liver cancer will receive either a transdiscal or paravertebral approach. The…

This study tests whether a single dose of NPX-5 (a psilocybin drug) combined with talk therapy can reduce severe anxiety in people who have trouble adjusting to a cancer diagnosis. About 87 adults aged 18–80 with moderate-to-severe anxiety will receive one of three doses (25 mg, …

This study tests whether using virtual reality (VR) can reduce severe belly pain and improve quality of life in people with digestive tract cancers. 360 participants will be split into three groups: one using a skills-based VR program, one using distracting VR videos, and a contr…

This study tests whether a smartphone app that lets cancer patients report their symptoms, combined with regular calls from a specially trained nurse, can help them better manage chemotherapy side effects and improve their quality of life. The study includes 414 adults with early…

This study tests whether fecal microbiota transplantation (FMT) – taking donor gut bacteria in capsules – can prevent or reduce gastrointestinal symptoms like nausea, vomiting, and diarrhea caused by chemotherapy or targeted therapy. It involves 90 adults with advanced (Stage IV)…

This study compares three routine pain control methods used during minimally invasive cancer surgery: a nerve block plus local anesthetic, nerve block alone, or local anesthetic alone. About 48 adults having surgery for various cancers will be randomly assigned to one of the thre…

This study tests a new device called the COMBO Endoscopy Oropharyngeal Airway in 580 obese patients undergoing sedated gastrointestinal endoscopy. The device combines oxygen delivery, breathing monitoring, and a bite block to prevent low oxygen levels. Researchers will compare it…

This study tests whether a special recovery plan (ERAS) helps people recover faster after minimally invasive stomach cancer surgery. The plan includes education before surgery, shorter fasting, early eating and walking, and less use of strong painkillers. Researchers will track h…

This study is for Black adults newly diagnosed with gastrointestinal cancer. It focuses on ensuring patients receive proper biomarker testing and evidence-based care, helping them find and join clinical trials if they choose, and providing easy-to-understand information about the…

This study looks at whether adding a geriatrician (a doctor who specializes in care for older adults) to cancer treatment can improve outcomes for people aged 70 and older with gastrointestinal cancers like stomach, colon, or pancreatic cancer. Researchers will test if an online …

This study tests whether giving heated chemotherapy directly into the abdomen (HIPEC) can increase a protein called PD-L1 on stomach cancer cells that have spread to the lining of the belly. Higher PD-L1 levels might make these cancers more responsive to immunotherapy drugs. The …

This study tests whether a new type of adaptive radiotherapy can reduce radiation exposure to the ovaries in young women (ages 18-50) receiving pelvic radiation for cancers like uterine, rectal, or cervical cancer. Using advanced imaging and an AI treatment planning system, resea…

This study aims to collect blood, urine, tumor samples, and health data from up to 1,000 people with malignant mesothelioma or other cancers that express a protein called mesothelin. Participants will be followed over time to track the course of their disease. The goal is to buil…

This study aims to develop and fine-tune a medical artificial intelligence (AI) model to assist with diagnosing and managing gastric, cardiovascular, and cerebrovascular diseases. Researchers will use a large dataset of patient records, medical images, and doctor-patient dialogue…

This study is testing whether a computer model that analyzes CT scans taken before treatment, combined with basic clinical information, can predict how long people with gastric cancer will live and when their cancer might progress. Researchers will follow 600 adults receiving sta…

This study tests whether tumor organoids grown from biopsies can predict how well patients with gastric or colon cancer and peritoneal carcinomatosis respond to hyperthermic intraperitoneal chemotherapy (HIPEC). Researchers collect tumor samples during standard surgery, grow them…

This study examines tissue samples from adults with gastric cancer who received chemotherapy before surgery. Researchers will analyze gene activity in the tumor and nearby lymph nodes to look for patterns linked to how well the cancer responded to treatment. The goal is to better…

This study investigates whether certain Helicobacter bacteria other than H. pylori are present in people with various stomach conditions, including chronic gastritis, precancerous changes, and gastric cancer. Researchers will analyze biopsy samples from about 150 patients to meas…

This study follows 400 people aged 6 and older who have a rare stomach cancer called GIST. Researchers will collect tumor tissue during surgery and study it in the lab to learn more about the disease. Participants are monitored every 6 to 12 months for up to 10 years before surge…

This study follows 130 adults undergoing surgery for stomach or esophageal cancer to see how often they experience postoperative delirium—a state of confusion and disorientation after anesthesia. Researchers will also check whether depression, frailty, poor nutrition, or muscle l…

This study looks at the bacteria living in the mouth, stool, and tumors of Colombian adults with advanced cancers of the stomach, colon, breast, cervix, or head and neck who are starting immunotherapy as standard care. Researchers will compare these microbial profiles to those of…

This study investigates whether a blood test can predict which stomach cancer patients will develop nerve damage (peripheral neuropathy) from the chemotherapy drug paclitaxel. Paclitaxel is a standard second-line treatment for advanced gastric cancer, but nerve damage is a common…

This study is testing a new blood test to find tiny traces of stomach cancer that might be left behind after surgery. The goal is to catch a recurrence earlier than standard scans. Researchers will collect blood samples from 500 people who had their stomach cancer removed and fol…

This study looks at whether giving the chemotherapy drug paclitaxel over a longer period (2-3 hours instead of 1 hour) can help cancer patients with low muscle mass achieve safer drug levels. Researchers will compare drug concentrations in 22 women with breast, stomach, or esopha…

This study investigates clonal hematopoiesis (CH) — small mutations in blood cells that can arise naturally or after cancer treatment — in adults receiving chemotherapy or radiation for solid tumors like breast, lung, or colorectal cancer. Researchers will collect blood, saliva, …

This study is building a huge registry of information and biological samples from adults with or at risk for many types of cancer, as well as healthy volunteers. Researchers will use this resource to study what causes cancer and how to better prevent, detect, and treat it. The re…

This study uses a special microscope called intravital microscopy to look at blood vessels inside solid tumors while patients are in surgery. Researchers want to see how these vessels work and how well they let blood and dye flow through. The goal is to learn whether tumor vessel…

This study is building a registry of people with gastric cancer, a family history of it, or a specific gene mutation (CDH1). Participants fill out online questionnaires and provide saliva, blood, or tissue samples. The goal is to learn more about what causes stomach cancer and ho…

Cancer patients face a higher risk of blood clots during chemotherapy, but it's hard to know who is most at risk. This study will measure clotting-related biomarkers in the blood of 380 patients with ovarian, lung, stomach, or pancreatic cancer at four points during their treatme…

This study aims to develop a model that uses genetic information from tumor tissue to predict how well gastric cancer patients will respond to chemotherapy. Researchers will analyze RNA splicing patterns and apply machine learning to identify patients who are less likely to benef…

This study is building a large database of 15,000 patients with esophageal or gastric cancers in France. Researchers will look back at medical records to see how patients fared after surgery, focusing on how long they stayed cancer-free. The goal is to learn more about survival, …

This study is testing whether a quick, non-invasive test that measures heart rate and breathing patterns before thoracic surgery can help predict which patients are more likely to have complications after the operation. Researchers will enroll 130 adults undergoing major chest su…

This study collects blood, urine, and bone marrow samples from 620 people with solid cancers like lung, colorectal, and pancreatic cancer. Researchers will look for tumor cells and DNA in these samples to understand how cancer spreads and why it sometimes comes back after surgery…

This study is investigating whether exposure to microplastics is linked to the development of stomach cancer and its early stages. Researchers will ask 450 people with different stomach conditions to fill out a detailed questionnaire about their possible exposure to microplastics…

This study is testing whether a personalized blood test that looks for tumor DNA can detect stomach cancer recurrence earlier than standard imaging. About 110 patients who had chemotherapy and surgery for stage II-III stomach cancer will give blood samples over time. The goal is …

This study compares different ways to reconnect the digestive tract after removing the upper part of the stomach due to cancer. The goal is to find which method causes the fewest complications and gives patients the best quality of life. Researchers will follow 400 people in Russ…

This study is not testing a new treatment. Instead, it follows up with 610 people who previously received cadonilimab for advanced gastric cancer in earlier trials. Researchers will collect long-term survival data to see if the drug's benefits last. No additional medication is gi…

This study looks at whether using a dye called indocyanine green (ICG) during surgery for advanced stomach cancer helps surgeons see cancer more clearly and change their approach. About 360 adults with stomach cancer will take part. The goal is to see if the dye improves how surg…

This study is developing an AI tool to predict the risk of serious bleeding after stomach cancer surgery. Researchers will collect data from 7,000 adult patients who had their stomach removed due to cancer. The goal is to help doctors decide earlier if a second surgery is needed,…

This study aims to understand why many cancer patients lose muscle and fat (cachexia), a condition that worsens their health. Researchers will use advanced techniques to analyze samples from 1000 adults with certain cancers. The goal is to find early warning signs and new targets…

This international registry collects data from 200 stomach cancer patients who undergo robot-assisted minimally invasive gastrectomy (RAMIG). The goal is to understand surgical techniques, outcomes, and the learning curve for surgeons. By standardizing data collection across cont…

This study looks at whether a blood test that detects tumor DNA (ctDNA) can help doctors monitor how well treatment is working in people with stomach cancer. About 600 participants will provide blood samples before and during treatment to see if changes in ctDNA levels predict re…

This study compares two types of staplers (linear vs circular) used to reconnect the esophagus to the small intestine after stomach removal surgery for gastric cancer. Researchers want to see which stapler leads to fewer complications and shorter surgery time. About 100 adults wi…

This study translates and validates a Korean quality-of-life questionnaire (KOQUSS-40) for Spanish-speaking patients who had stomach cancer surgery. Researchers will enroll 505 adults who are at least one month past surgery and cancer-free. The goal is to create a reliable tool t…

This study tests whether a large language model (AI) can help junior doctors write more accurate and efficient cancer treatment reports. Forty doctors will be split into two groups: one using AI assistance, the other using traditional methods. The reports will be scored by expert…

This study looks at how common Helicobacter pylori infection is in people newly diagnosed with stomach cancer in Martinique. Researchers will collect tumor samples, healthy tissue, and blood to build a biobank. The goal is to understand why stomach cancer is more common in the We…

This observational study will follow 1,000 adults in Algeria who have been diagnosed with gastric cancer. Researchers will collect information on patient demographics, risk factors, symptoms, how the cancer is diagnosed, and what treatments are used. The goal is to better underst…

This study looks at tissue samples from 30 adults with stomach or esophageal cancer that spread to the brain. Researchers compare the genetic markers of the original tumor and the brain tumor to see if they differ. The goal is to better understand how these cancers change when th…

This pilot study is testing whether a combination of a breath test for H. pylori bacteria, questionnaires, and an upper endoscopy can identify people at high risk for stomach cancer. The study will enroll 240 racial minority adults aged 40-80. The goal is to see if this screening…

This study aims to develop a simple tool to predict whether a person's stomach will still have food or liquid in it before a sedated endoscopy. Having a full stomach during sedation raises the risk of serious complications like choking. Researchers will study 5,000 adults to iden…

This study collects tissue, blood, urine, and stool samples from 5000 people undergoing colonoscopy or endoscopy, including those with cancer, polyps, or inflammatory bowel disease, as well as healthy volunteers. The goal is to find new biomarkers that could improve early detecti…

This study looks at how well patients understand the information they get before major abdominal cancer surgery and whether that affects regret afterward. Researchers will survey 90 adults before surgery, then one month and three months after. The goal is to improve how doctors c…

This study follows 3,000 adults aged 40 and older who carry Helicobacter pylori, a common stomach bug. Researchers want to see if people with certain high-risk subtypes of the bacteria develop stomach cancer more often than those with other subtypes or no infection. Participants …

This study uses a 20-25 minute survey to find out which features of diagnostic tests for gastro-esophageal cancer matter most to patients and the general public. Researchers aim to understand preferences and regional differences to improve screening decisions. About 2,200 adults …

This study is testing whether a monthly blood test can predict dangerous blood clots in people with certain cancers (lung, pancreatic, stomach, or brain). Cancer patients are at high risk for clots, which can be deadly. Researchers will follow 200 participants for 12 months, taki…

This study is looking at whether the bacteria in your gut can predict how well a combination of immunotherapy and chemotherapy works for advanced stomach cancer. Researchers will track 300 patients and check their gut bacteria at several points during treatment. The goal is to fi…

This study looks at people with a specific genetic change in the CTNNA1 gene, which may increase the risk of stomach and breast cancers. Researchers will collect family health histories from 100 participants to better understand these risks. The goal is to improve cancer screenin…

This study is looking for markers in the blood that might show early signs of stomach cancer or conditions that can lead to it. Researchers will follow about 192 adults who are already getting stomach function tests. The goal is to see if changes in these markers over time can he…

This study is building a registry of 3,200 people with early changes in the stomach lining that can lead to gastric cancer. Researchers will collect information on lifestyle, diet, and other risk factors through questionnaires. The goal is to better understand why some people dev…

This study looks back at 1,200 people who had a breathing tube placed during surgery to find out how often voice box injury happens and what makes it more likely. Researchers will check medical records and call patients to see if they had hoarseness or other throat problems after…

This study is observing 50 adults with advanced cancers (lung, breast, colorectal, gastric, or liver) who are starting immunotherapy. Researchers want to see if changes in ctDNA (bits of tumor DNA in the blood) can predict early whether the treatment is working. They will also ch…

This study looks at using endoscopic vacuum therapy to treat leaks that can happen after stomach cancer surgery. Researchers will track 100 patients to see if this approach lowers death rates, reduces complications, and improves patient satisfaction. The goal is to find a better …

This study at Stanford University collects tissue and blood samples from 100 adults with or at high inherited risk for stomach, esophageal, or related cancers. Researchers aim to understand how genes and proteins contribute to cancer development. The study does not test any treat…

This study follows 600 people at higher risk for stomach cancer to track precancerous changes in the stomach lining. Researchers collect tissue, blood, and saliva samples during routine endoscopies. The goal is to understand why some people's stomach changes progress to cancer wh…

This study follows 200 people with cancers of the esophagus, stomach, pancreas, colon, or rectum who are scheduled for surgery, along with some healthy controls. Researchers will track weight, muscle mass, physical activity, quality of life, and immune markers over a year to bett…

This study tests a new method to help choose cancer drugs for people with hard-to-treat solid tumors. Doctors take a small piece of the tumor, grow it in the lab, and test many drugs on it to see which works best. Then they give that drug to the patient. The goal is to see if thi…

This study looks at how well certain markers in tumors can predict whether a type of targeted cancer treatment called antibody-drug conjugates (ADCs) will work. About 400 adults with advanced breast, stomach, bladder, or lung cancer will provide tumor samples before and after tre…

This study looks at 100 adults in Guadeloupe who have just been diagnosed with stomach cancer. Researchers want to find out how many of them also have an H. pylori infection, a bacteria linked to stomach cancer. By testing tissue and blood samples, they hope to learn more about t…

This study is testing whether an artificial intelligence (AI) tool can help match cancer patients with the right clinical trials. Researchers will enroll up to 50,000 people with various cancers to see if the AI improves trial enrollment rates and patient outcomes. The goal is to…

This study collects samples from 320 people, including those with solid cancers (like lung, colon, or pancreatic cancer) and those undergoing lung cancer screening, to look for cancer cells and DNA in blood, urine, and bone marrow. The goal is to learn how cancer spreads and find…

This study collects and stores tissue and blood samples from people with stomach, esophageal, pancreatic, liver, and other gastrointestinal cancers. The goal is to build a large database of samples and medical information to help researchers understand these cancers better. Parti…

This study aims to find the best range for removing No.4sb lymph nodes during surgery for advanced stomach cancer. Researchers will track 400 patients to see how often cancer spreads to different parts of these lymph nodes. The goal is to help surgeons remove only the necessary n…

This study is testing whether measuring ctDNA (bits of tumor DNA) in blood or stool can help doctors manage patients with cancers of the digestive tract, including pancreas, colon, and bile duct cancers. Researchers will track survival and see how these markers relate to outcomes…

This study is observing 150 people with stomach cancer who are having surgery to remove the stomach and nearby lymph nodes. The goal is to see how often cancer spreads to a specific group of lymph nodes near the stomach. The findings could help doctors decide exactly which lymph …